Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

Abstract Number: 1447 • ACR Convergence 2021
Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement
S. Reza Jafarzadeh¹, Tuhina Neogi¹ and David Felson², ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, MA
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are a primary treatment for osteoarthritis (OA). It is uncertain, however, whether regular use of NSAIDs affects the risk of…
Abstract Number: 1920 • ACR Convergence 2021
Association of C-reactive Protein and Non-Steroidal Anti-inflammatory Drugs with Cardiovascular Events in Patients with Psoriatic Arthritis: A Time-dependent Cox Regression Analysis
Ho Man Lam¹, Ho So², Isaac Cheng¹, Edmund Li¹, Priscilla Wong³, Tena Li¹, Alex Lee¹ and Lai-Shan Tam⁴, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²CUHK, Hong Kong, China, ³Prince of Wales Hospital, Hong Kong, Hong Kong, ⁴Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are…
Abstract Number: 0058 • ACR Convergence 2021
Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
Sophie Hecquet¹, Perle Totoson², Maude Tournier², Clement Prati¹, Daniel Wendling¹, Céline Demougeot² and Frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France
Background/Purpose: The intestine is no longer considered as an organ targeted by spondyloarthritis (SpA) but also an actor of the disease alongside environmental and immunological…
Abstract Number: 0483 • ACR Convergence 2021
Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs
Tuhina Neogi¹, Andrea Dell'isola², Martin Englund² and Aleksandra Turkiewicz², ¹Boston University School of Medicine, Boston, MA, ²Lund University, Lund, Sweden
Background/Purpose: Oral NSAIDs are recommended for OA management. However, many patients with OA have contraindications to NSAIDs or have comorbidities that warrant precaution. Because few…
Abstract Number: 0728 • ACR Convergence 2021
Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
Philip Conaghan¹, Xavier Chevalier², Linda Mindeholm³, Ursula Schramm³, Jens Praestgaard³, Abdelkader Seroutou³, Ronenn Roubenoff³ and Matthias Schieker³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, ³Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
Abstract Number: 1326 • ACR Convergence 2020
Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study
Sali Merjanah¹, Mohamad Bittar² and Marina Magrey³, ¹Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, ²The University of Tennessee Health Science Center, Memphis, TN, ³Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…
Abstract Number: 1375 • ACR Convergence 2020
Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?
Charlotte Baert¹, Charlene Mouafo Toukam², Tatiana Sokolova³, Maria S. Stoenoiu⁴, Patrick Durez⁵, Laurent Meric De Bellefon² and Adrien Nzeusseu Toukap⁶, ¹Rheumatology department, St-Luc university hospitals, Brussels, Belgium, ²Rheumatology department; St-Luc University Hospitals, Brussels, Belgium, ³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴1Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, ⁵Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁶1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium
Background/Purpose: Randomized-controlled trials (RCTs) done in axial spondyloarthritis (AxSpA) patients have shown that remission in Ankylosing Spondylitis and nonradiographic AxSpA patients treated without biologics (BIOL)…
Abstract Number: 1635 • ACR Convergence 2020
Profile of Topical Diclofenac Sodium Gel 1% (Voltaren®) Users in a United States Longitudinal Electronic Health Records Database
Amy Kenneally¹, Frédérique Bariguian², Richard Petruschke¹, Arlene Tave³, Jess Edison⁴, Nicholas M. Sicignano⁵ and Francis Barbone¹, ¹GSK Consumer Healthcare, Warren, NJ, ²GSK Consumer Healthcare S.A., Nyon, Switzerland, ³PharmaLex US Corporation, Fairfax, VA, ⁴Walter Reed National Military Medical Center, Bethesda, ⁵Health ResearchTx LLC., Prevose, PA
Background/Purpose: Diclofenac sodium gel 1% (DSG), a topical non-steroidal anti-inflammatory drug (NSAID), is effective for the relief of osteoarthritis (OA) pain in the elbows, wrists,…
Abstract Number: 1646 • ACR Convergence 2020
Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events
Jayeshkumar Patel¹, Wenhui Wei², Raveendhara Bannuru³, Ravi Iyer⁴, Nazneen Fatima Shaikh¹, Traci LeMasters¹, Chibuzo Iloabuchi¹, Degang Wang² and Usha Sambamoorthi¹, ¹West Virginia University School of Pharmacy, Morgantown, WV, ²Regeneron Pharmaceuticals, Tarrytown, NY, ³Tufts Medical Center, Boston, MA, ⁴Teva Pharmaceutical Industries, West Chester, PA
Background/Purpose: NSAIDs are commonly used for OA pain, but the benefits of pain relief must be carefully weighed against the potential risk for gastrointestinal (GI),…
Abstract Number: 1852 • ACR Convergence 2020
Intestinal Permeability in the Adjuvant Induced Arthritis Model: Preliminary Study and Impact of NSAIDs
Sophie Hecquet¹, Romain Bordy², Clement Prati¹, Daniel Wendling³, Céline Demougeot² and Frank Verhoeven¹, ¹Rheumatology, University Teaching Hospital, Besançon, France, ²EA4267 Laboratory, Besançon, France, ³CHU Besançon, department of rheumatology, Besancon, France
Background/Purpose: The gut is no longer considered as a simple element associated with spondyloarthritis but as a real actor of the disease. In patients with…
Abstract Number: 1873 • ACR Convergence 2020
The Changing Profile of Ankylosing Spondylitis in the Biologic Era
Lauren Ridley¹, Michael Weisman², Lianne Gensler³, Michael Ward⁴, Mark Hwang⁵, Amirali Tahanan⁶, MinJae Lee⁷, Mohammad Rahbar⁶, Mariko Ishimori⁸, Matthew Brown⁹ and John Reveille¹⁰, ¹McGovern Medical School at UTHealth, Houston, TX, ²Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University of California San Francisco, San Francisco, CA, ⁴National Institutes of Health, Bethesda, MD, ⁵McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁶McGovern Medical School at UTHealth, Houston, ⁷UT Southwestern, Dallas, ⁸Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ¹⁰Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: To compare disease characteristics, comorbidities, and medication utilization of 573 patients with ankylosing spondylitis (AS) with short (< 20 years) disease duration (from symptom…
Abstract Number: 2023 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Atul Deodhar¹, Désirée van der Heijde², Joachim Sieper³, Filip Van den Bosch⁴, Walter Maksymowych⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Östör⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Xin Wang¹⁰, Alvina D. Chu¹¹ and In-Ho Song¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Leiden University Medical Center, Leiden, Netherlands, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Ghent University Hospital, Ghent, Belgium, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Seoul-t'ukpyolsi, Republic of Korea, ⁷Department Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, ⁹University of Montpellier, Montpellier, France, ¹⁰AbbVie Inc., North Chicago, IL, ¹¹AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib (UPA), a Janus kinase (JAK) inhibitor, was efficacious and well tolerated vs placebo (PBO) during the first 14 weeks (wks) of the phase…
Abstract Number: 1097 • 2019 ACR/ARP Annual Meeting
Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Lingyi Li¹, Na Lu ¹, Jacek Kopec ², John Esdaile ³, Hui Xie ⁴ and J. Antonio Avina-Zubieta ², ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are prescribed for the management of pain among patients with rheumatic diseases including systemic lupus erythematosus (SLE). However,…
Abstract Number: 2195 • 2019 ACR/ARP Annual Meeting
BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Joel A. Block¹, Bharat Patel ² and Sandy Yacoub Garas ³, ¹Rush University Medical Center, Chicago, IL, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ
Background/Purpose: Clinical trials demonstrate that diclofenac sodium gel 1% (DSG 1%), a topical NSAID, provides significantly better pain relief than vehicle placebo for patients with…
Abstract Number: 2197 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Marc C. Hochberg¹, Bharat Patel ², Sandy Yacoub Garas ³ and Roy Altman ⁴, ¹University of Maryland School of Medicine, Baltimore, MD, ²GlaxoSmithKline Consumer Healthcare, Weybridge, United Kingdom, ³GlaxoSmithKline Consumer Healthcare, Warren, NJ, ⁴University of California, Los Angeles
Background/Purpose: Topical agents are recommended for the initial treatment of patients with knee osteoarthritis (OA). Diclofenac sodium gel 1% (DSG 1%), a topical nonsteroidal anti-inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].